J.P. Morgan Executive Roundtable, Part 1: How To Help Women Move Into The Biopharma C-Suite

Scrip decided to shake things up a bit for its third annual biopharmaceutical executive roundtable held during the J.P. Morgan Healthcare Conference by putting together an all-female panel to talk about the financing and dealmaking landscape as well as the state of women in the industry.

chemist

Emma Walmsley’s elevation to the CEO role at GlaxoSmithKline PLC– the first female CEO of a big pharma company when she moves into the post later this year – is coming at a time when there’s a renewed focus on gender diversity in the biopharmaceutical C-suite. And it is an issue that isn’t going away.

After two years in a row of all-male roundtable discussions at Scrip’s annual biopharmaceutical executive roundtable at the J.P. Morgan...

More from Leadership

More from Scrip

2025’s Biggest Launches – Half-Year Progress Report

 

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.